Not surprisingly, RWD of survival for HER2 positive advanced breast cancer in Brazil has been estimated at 23 months while it is in excess of 50 months in the data presented from France where the treatment is available to all patients with the indication [25]. Here, ERBB2 is linked to breast cancer.